Nonfibrotic Hypersensitivity Pneumonitis with Active Inflammation: When Exposure Avoidance Has Not Improved Lung Function
This protocol applies to patients with inflammatory (nonfibrotic) Bird fancier's lung — hypersensitivity pneumonitis showing features of active inflammation such as ground glass opacities on HRCT, bronchoalveolar lavage lymphocytosis, or acute to sub-acute symptom onset — in the absence of pulmonary fibrosis, where the first-line approach has not achieved its goal.
Clinical Scenario
International diagnostic guidelines classify hypersensitivity pneumonitis into fibrotic and nonfibrotic phenotypes based on the presence or absence of radiological and histopathological fibrosis — a distinction that carries important prognostic and treatment implications. In the nonfibrotic (inflammatory) phenotype, findings such as ground glass opacities on HRCT, BAL lymphocytosis, and a well-documented avian exposure history with acute or sub-acute symptom onset define the presentation.
First-Line Treatment Did Not Reach Its Goal
The initial approach for avian-associated hypersensitivity pneumonitis is identification and complete removal of causative exposures — including birds, feathers, and droppings, along with a thorough deep clean of soft furnishings. The target of that step is improvement in lung function following exposure removal.
When lung function does not improve after exposure avoidance has been implemented, further management is indicated. This protocol defines the next step.
Treatment Approach (Partial Overview)
For patients with persistent features of inflammation despite prior exposure avoidance, a systemic pharmacological approach is indicated. The regimen is centred on corticosteroid therapy, with the strategy determined by the severity and acuity of the presentation. The complete sequence, full range of options, and monitoring plan are available in the structured protocol.
Clinical Goals
Treatment success is defined as improvement or stabilisation in clinical symptoms and lung function (FVC), evaluated at re-assessment between 6 and 12 weeks after initiation.
References
DOI: 10.1111/resp.14847
Moderate-to-high dose systemic corticosteroids would usually be considered for HP patients with features of inflammation (e.g., GGO on HRCT, BAL lymphocytosis, well-documented exposure with acute or sub-acute symptom onset).
Recently published international diagnostic guidelines recommend HP classification into fibrotic or nonfibrotic phenotypes based on the presence or absence of radiological and/or histopathological fibrosis, supported by the observation that pulmonary fibrosis conveys important prognostic and treatment implications.
For rapid onset pneumonitis with severe physiologic compromise, induction therapy may comprise of pulsed-dose intravenous methylprednisolone, followed by high-dose oral corticosteroids and often steroid-sparing agents (see below).
Following corticosteroid initiation, timely re-evaluation (e.g., between 6 and 12 weeks) is important to ensure improvement or stabilization in clinical symptoms and lung function, and to manage steroid-related side effects.
View source ↗